7RG0 Stock Overview A clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Regulus Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Regulus Therapeutics Historical stock prices Current Share Price US$1.14 52 Week High US$3.26 52 Week Low US$0.83 Beta 1.58 1 Month Change -19.72% 3 Month Change -20.28% 1 Year Change -23.49% 3 Year Change -35.96% 5 Year Change -85.38% Change since IPO -99.86%
Recent News & Updates
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease Program for Farabursen (RGLS8429) Jan 29
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Oct 08
New minor risk - Profitability Aug 15
New major risk - Revenue and earnings growth Jun 25
Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 24
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration May 23 See more updates
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease Program for Farabursen (RGLS8429) Jan 29
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Oct 08
New minor risk - Profitability Aug 15
New major risk - Revenue and earnings growth Jun 25
Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 24
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration May 23
Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer May 18 Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million. May 11
Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024 Apr 21
New major risk - Revenue and earnings growth Mar 19
New major risk - Shareholder dilution Mar 17
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors Mar 15 Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors
Insufficient new directors Dec 20
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Nov 03
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd) Sep 14
New major risk - Financial position Aug 10
Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Jun 28
Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development Jun 13
Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease May 17
Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member Dec 13
Regulus Therapeutics Inc. Announces Executive Changes Nov 30
Insufficient new directors Nov 16
Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Nov 03
Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Sep 13
Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Insufficient new directors Aug 01
Insufficient new directors Jul 02
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease Jun 22
Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Jun 14
Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease May 12
Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 12
Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome Feb 25
Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429 Jan 22
Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc. Dec 01
Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc. Nov 25
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Director Jason Nunn has joined 5th company board Sep 02
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 Jun 26
Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021 Jun 22
Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program May 22
Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) May 04
Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019) Mar 10
Revenue beats expectations Mar 10
New 90-day high: €1.58 Feb 18
Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease Feb 11
Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors Jan 28
New 90-day high: €1.32 Jan 28
New 90-day high: €0.84 Dec 08
Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development Dec 03
Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding Dec 02
New 90-day high: €0.52 Nov 22
Revenue beats expectations Nov 07
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Oct 16
New 90-day low - €0.38 Sep 02
New 90-day low - €0.53 Aug 15
First half earnings released Aug 14
New 90-day high - €0.84 Jul 20 Shareholder Returns 7RG0 DE Biotechs DE Market 7D -14.3% 1.2% 2.3% 1Y -23.5% -5.6% 16.7%
See full shareholder returns
Return vs Market: 7RG0 underperformed the German Market which returned 15% over the past year.
Price Volatility Is 7RG0's price volatile compared to industry and market? 7RG0 volatility 7RG0 Average Weekly Movement 16.7% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 7RG0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7RG0's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Show more Regulus Therapeutics Inc. Fundamentals Summary How do Regulus Therapeutics's earnings and revenue compare to its market cap? 7RG0 fundamental statistics Market cap €75.82m Earnings (TTM ) -€40.15m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7RG0 income statement (TTM ) Revenue US$0 Cost of Revenue US$22.62m Gross Profit -US$22.62m Other Expenses US$19.01m Earnings -US$41.63m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 13:04 End of Day Share Price 2025/02/11 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Birchenough BMO Capital Markets Equity Research James Birchenough BMO Capital Markets U.S. (Historical) Madhu Kumar B. Riley Securities, Inc.
Show 14 more analysts 
